Clear.bio, founded in 2019, has developed an innovative blended-care solution that combines a real-time sensor, an advanced app, and the support of a registered dietitian. While real-time glucose monitoring itself is not new, Clear.bio distinguishes itself through proprietary algorithms, AI-driven insights, a unique nutritional score, and a dedicated consumer app. This approach has delivered exceptional clinical results at low production costs, making it widely accessible to the 70 million people in Europe living with early-stage T2D.

Clear.bio is recognized as a leader in real-time glucose monitoring within the medical world. The solution is covered by statutory health insurance in the Netherlands and is already prescribed by hundreds of doctors. Watch this video in which the founders, Piet Hein van Dam and Madelon Bracke describe Clear.bio.

Clear.bio was introduced to us in January 2025 by Maarten Broekema, an angel investor and entrepreneur. After reviewing the available information, we gathered feedback from our Producers of Good Business and Producers of Good Money, who were generally enthusiastic about the company. They asked a few questions about the impact focus and the regulatory challenges. We concluded that both the case and the team were promising, but that we needed a Producer of Good Business with a strong medical and entrepreneurial background. This proved to be an excellent opportunity for our Mind Peter de Vries . We then conducted an intake interview with Piet Hein (co-founder and CEO), along with Ronald Beuk and Peter de Vries.

Clear.bio approached us with a funding challenge: they were seeking €1.7 million in investment for rollout in the Netherlands, regulatory approvals in France and Germany, accelerated market access to these countries, and the implementation of a post-treatment/relapse prevention solution.

When we first met, Clear.bio had already closed the first part of its funding round (€180.000) and was about to close a second round of approximately €500.000. They also had significant non-dilutive funding opportunities in the pipeline (approximately €850.000), some of which could only be activated if an equal amount of equity was injected. With a mid-July deadline to secure at least €230.000 to release the grant, we had four months to raise the capital.

At the same time, we have committed to a long-term partnership between Clear.bio and Generous Minds after the financing is secured, to enable the relevant experts from our cooperative to support the company's further growth.

As of April 10 2025, we have identified and approached 82 investors with the Clear.bio case. We received feedback from approximately 50 investors, spoke with at least 10, and onboarded several others, while also investing ourselves through Generous Minds with a Ticket of Trust. In line with our Integrated Capital approach, we now have several leads and investors who have expressed genuine interest in participating in the next funding round.

The direct investment came from informal investors—both independent angel investors and members of investment groups like Money Meets Ideas and Kaasstad Kapitaal, with whom we regularly collaborate. Generous Minds' Ticket of Trust proved to be a catalyst just before the deadline by helping to convince the remaining investors. Ultimately, Generous Minds helped Clear.bio successfully raise €1.7 million.

The financing round was led by Ronald Beuk as producer of Good Money,Jurek Hryniuk as intermediate producer of Good Money, Brian Kwakman in his role within the Generous Money team, and Peter de Vries as producer of Good Business, who observed our process and supported us with insights based on his experiences in the field.

After celebrating this success, we're continuing our collaboration. Clear.bio is now preparing its most pressing questions and challenges, which we'll translate into carousel meetings with relevant Minds experts. We look forward to seeing even more Minds contribute to Clear.bio's wonderful mission.

With its current runway, Clear.bio can operate for almost two years. However, with a solid plan for rapid expansion and deeper market penetration in the Netherlands, we expect the company to grow faster than anticipated, making the need for another round of funding to increase its impact likely sooner. We look forward to Clear.bio's next steps and impact!